

RECEIVED
CENTRAL FAX CENTER
FEB 16 2007

MARSHALL, GERSTEIN & BORUN LLP
ATTORNEYS AT LAW
6300 SEARS TOWER
233 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606-6357
(312) 474-6300
FAX: (312) 474-0448

02/16/2007

FACSIMILE TRANSMISSION SHEET

TO:

USPTO

571 273 8300

FROM: Sharon M. Sintich

RE: 30847/2051-004

PAGES (INCLUDING THIS PAGE): 3

Please see attached.


If you do not receive all pages of this fax in good condition, please contact Jill Schumerth at (312) 474-6300.

This transmission contains confidential information intended only for the addressee. If you are not the addressee, any disclosure or use of this information by you is strictly prohibited. If you have received this facsimile in error, please notify us by telephone immediately.

RECEIVED
CENTRAL FAX CENTER

FEB 16 2007

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted by facsimile to the Patent and Trademark Office, facsimile no. (571) 273-8300, on the date shown below.

Dated: February 16, 2007 Signature 
(Sharon M. Slinch)

Docket No.: 30847/2051-004
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Anna Helgadottir et al.

Confirmation No.: 6429

Application No.: 10/769,744

Art Unit: 1634

Filed: January 30, 2004

Examiner: D. Johannsen

For: **SUSCEPTIBILITY GENE FOR
MYOCARDIAL INFARCTION, STROKE,
AND PAOD; METHODS OF TREATMENT**

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

The restriction requirement set forth in the Office Action mailed January 16, 2007, requires the election of a compound species, a disease or condition species, administration step species and a selection step species. This response is timely filed.

The Examiner stated that claims 206 and 210-213 encompass multiple distinct compound species. Applicants hereby elect the compound species BAY-X-1005 for examination in the above-identified application. Claims 211-213 recite the elected species compound BAY-X-1005. Claims 206, 208, 209, 216, 217 and 225 generically encompass the elected compound species.

In addition, the Examiner stated that claims 206 and 209 encompass multiple different diseases or conditions. Applicants hereby elect the disease myocardial infarction (MI) for examination in the above-identified application. Claims 206, 208, 209, 211-213, 216, 217 and 225 encompass the elected disease of MI.

The pending claims assertedly encompass multiple different modifications in the administration step. In particular, Applicants are required to elect a monitoring step that is carried out before and during the administration step, e.g. monitoring the level of